Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Launched by MEDICAL UNIVERSITY OF VIENNA · Jun 27, 2008
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women over 18 years
- • Unilateral or bilateral primary open angle glaucoma, ocular hypertension, exfoliation glaucoma, pigmentary glaucoma with IOP between 22 -35mmHg
- • At least 3 reliable visual field testings
- • 4 weeks for ß adrenergic receptor antagonists and prostaglandin analogues, 2 weeks for adrenergic agonists, and 5 days for cholinergic agonists and carbonic anhydrase inhibitors
- Exclusion Criteria:
- • History of acute angle closure
- • Closed or barely open anterior chamber angle
- • Mean deviation of visual field testing \> 10
- • Intraocular surgery or argon laser trabeculoplasty within the last six months
- • Ocular inflammation or infection within the last three months
- • Contact lenses
- • Patients with bradycardia (heart rate \< 50 beats/min)
- • Second and third degree heart block
- • Asthma
- • COPD
- • Congestive heart failure
- • Severe renal impairment (creatinine clearance \< 1.8 L/h)
- • History of hypersensitivity to one of the study drugs or drugs with similar chemical structure
- • Topical or systematically/oral therapy with steroids
- • History of non-IOP responder to beta-blockers, alpha-2 adrenergic or prostaglandin analogues
- • Pregnancy
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Michael Wolzt, MD
Principal Investigator
Department of Clinical Pharmacology, Medical University of Vienna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials